期刊文献+

依帕司他治疗糖尿病感觉神经病变的临床疗效观察 被引量:3

The therapeutic effect of diabetic sensory neuropathy treated with epalrestat
下载PDF
导出
摘要 目的观察依帕司他治疗糖尿病感觉神经病变的临床疗效。方法选择2型糖尿病周围神经病变患者34例。测定治疗前后腓总神经及胫总神经传导速度。结果 61%的受试者治疗前腓总神经感觉神经传导速度减慢,治疗后32%的受试者该神经传导速度减慢;97%的受试者治疗前胫总神经感觉神经段1传导速度减慢,治疗后65%的受试者该神经传导速度减慢;腓总神经感觉神经治疗后其神经传导速度较治疗前明显增快,胫总神经感觉神经运动节段1在治疗后其神经传导速度较治疗前明显增快。结论口服依帕司他是治疗糖尿病周围神经病变的有效手段之一。 Objective This study observed the clinical curative effects of aldose reductase inhibitor epalrestat in treat- ment of diabetic sensory neuropathy. Methods Thirty-four diabetic sensory neuropathy patients were selected. The nerve electrophysiological data were collected before and after treating with epalrestat. Results The ratios of nerve con- ductive velocity in peroneal nerve sensory showed slowing down than normal before and after the treatment, which were respectively 61% and 32%; The ratios of the nerve conductive velocity in tibial nerve sensory nerve segment 1 showed slowing down before and after the treatment,which were respectively 97% and 65%; The nerve conductive velocity of the peroneal sensory nerve after treatment was significantly faster than that before treatment, the nerve conductive ve- locity of the the tibial nerve sensory nerve motion segments in 1 after treatment was significantly faster than that before treatment. Conclusion Epalrestat is one of the effective methods in the treatment of diabetic peripheral neuropathy.
出处 《中国现代医生》 2014年第26期55-57,共3页 China Modern Doctor
关键词 糖尿病 周围神经病变 依帕司他 神经传导 Diabetes mellitus Peripheral neuropathy Epalrestat Nerve conduction
  • 相关文献

参考文献15

  • 1Morales-Vidal S, Morgan C, McCoyd M, et al. Diabetic peripheral neuropathy and the management of diabetic peripheral neuropathic pain[J]. Postgrad Med,2012, 124 (4):145-153.
  • 2Maladkar M, Rajadhyaksha G, Venkataswamy N, et al. Efficacy, safety, and tolerability of Epalrestat compared to Methylcobalamine in patients with diabetic neuropathy[J]. Int J Diabetes Dev Ctries,2009, 29 (1):28-34.
  • 3Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy[J]. J Diabetes Investig, 2011, 2(1):33-42.
  • 4Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reduc- tase inhibitors in the treatment of diabetic peripheral neu- ropathy: a review[J]. J Diabetes Complications, 2010, 24 (5):354-360.
  • 5Yagihashi S. Recent advances in clinical practice and in basic research on diabetic neuropathy[J]. Brain Nerve, 2011, 63(6) : 571-582.
  • 6Pop-Busui R1, Sima A, Stevens M. Diabetic neuropathy and oxidative stress[J]. Diabetes Metab Res Rev,2006, 22(4):257-273.
  • 7Kawai T, Takei I, Tokui M, et al. Effects of epalrestat, an aldose reduetase inhibitor, on diabetic peripheral neuro pathy in patients with type 2 diabetes, in relation to suppression of N-earboxymethyl lysine[J]. J Diabetes Com- plications, 2010,24 (6):424-432.
  • 8Nirogi R, Kandikere V, Ajjala DR, et al. LC-MS/MS method for the quantification of aldose reductase in- hibitor-epalrestat and application to pharmacokinetic study[J]. J Pharm Biomed Anal,2013, 74:227-234.
  • 9Ito A, Ishii-Nozawa R, Ibuki C, et al. Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course [J]. Yakugaku Zasshi, 2009, 129(10):1239-1247.
  • 10Ohmura C, Watade H, Azuma K, et al. Aldose reduct ase inhibit or, epalrestat, reduces lipid hydroperoxides in type 2 diabetes[J]. Endocr J, 2009, 56(1):149-156.

二级参考文献28

共引文献23

同被引文献24

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部